Aurinia (AUPH) director Form 4: 6,039 shares withheld
Aurinia Pharmaceuticals Inc. (AUPH) reported an insider equity transaction on a Form 4 involving one director.
Rhea-AI Filing Summary
Aurinia Pharmaceuticals Inc. (AUPH) reported an insider equity transaction on a Form 4 involving one director. On 11/21/2025, the director had 6,039 common shares withheld at a price of $15.68 per share to cover tax withholding obligations tied to the vesting of restricted stock units. After this tax-related withholding, the director directly beneficially owned 14,592 common shares of Aurinia. This event reflects routine equity compensation and tax management rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Shares | 6,039 | $15.68 | $95K |
Footnotes (1)
- F1. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Aurinia Pharmaceuticals (AUPH) report on this Form 4?
Aurinia Pharmaceuticals reported that a director had 6,039 common shares withheld on 11/21/2025 to satisfy tax withholding obligations from vesting restricted stock units.
Was this Aurinia (AUPH) Form 4 transaction an open-market sale or purchase?
No. The Form 4 states that the 6,039 shares represent shares withheld to satisfy tax withholding obligations upon vesting of restricted stock units, not an open-market trade.
What is the reporting person’s relationship to Aurinia Pharmaceuticals (AUPH)?
The reporting person on this Form 4 is identified as a Director of Aurinia Pharmaceuticals Inc.
Does this Aurinia (AUPH) Form 4 indicate joint filing by multiple insiders?
No. The filing indicates that the Form is filed by one reporting person, not by more than one reporting person.
AI-generated analysis. How Rhea-AI works. Not financial advice.